Angina Pectoris Drugs Market Report 2026

The angina pectoris drugs market size has grown strongly in recent years. It will grow from $12.88 billion in 2025 to $13.63 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to increasing prevalence of coronary heart disease, rising awareness of angina symptoms, introduction of beta-blockers, expansion of hospital infrastructure, growing adoption of calcium channel blockers.

The angina pectoris drugs market size is expected to see strong growth in the next few years. It will grow to $17.67 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to advancements in precision medicine, growth of wearable cardiac monitoring devices, rising demand for combination therapies, increased investment in r&d for anti-ischemic agents, telehealth integration in cardiac care. Major trends in the forecast period include personalized angina management, minimally invasive drug delivery systems, fixed-dose combination therapies, growing geriatric patient population, telemedicine and remote cardiac monitoring.

The growing prevalence of cardiovascular diseases is anticipated to drive the expansion of the angina pectoris drug market in the coming years. Cardiovascular diseases include a broad group of disorders affecting the heart and blood vessels, such as coronary artery disease, hypertension, heart failure, and stroke. The rising incidence of cardiovascular diseases can be linked to multiple factors, including an aging population, unhealthy lifestyle habits, and increasing obesity rates. Angina pectoris drugs, including nitrates, beta-blockers, and calcium channel blockers, are effective in alleviating chest pain and discomfort resulting from reduced blood flow to the heart, thereby improving patients’ overall quality of life. For example, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted mortality rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, reflecting a 4% increase from 224.4 per 100,000 in 2023. Hence, the rising burden of cardiovascular diseases is contributing to the growth of the angina pectoris drug market.

The rising prevalence of diabetes is also expected to support the growth of the angina pectoris drug market over the forecast period. Hypertension, commonly referred to as high blood pressure, is a medical condition characterized by persistently elevated arterial pressure, while diabetes is a chronic disorder defined by abnormally high blood glucose levels. Both diabetes and hypertension are widely recognized risk factors for cardiovascular diseases, including angina pectoris. An increase in the prevalence of these conditions leads to greater demand for angina treatment medications. For example, in June 2024, according to the National Health Service, a UK-based government department, more than half a million additional individuals in England were identified in 2023 as being at risk of developing type 2 diabetes, increasing the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This marked a notable rise compared to 3,065,825 cases in 2022, representing an increase of nearly 20%. Therefore, the growing rates of diabetes are driving the expansion of the angina pectoris drug market.

Leading companies operating in the angina pectoris drug market are concentrating on the adoption of new technologies to maintain their competitive position, including securing regulatory approvals such as those from the U.S. Food and Drug Administration for treatments targeting angina and better addressing patient needs. Nitrostat (Nitroglycerin Sublingual Tablets) has received authorization from the United States Food and Drug Administration for the rapid treatment of angina pectoris or for the acute prevention of angina episodes. For instance, in March 2023, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, introduced Labetalol Hydrochloride Injection, USP, in a prefilled syringe format. This product was approved by the United States Food and Drug Administration and is used in hospital settings, where the 10 mg/2 mL prefilled syringe formulation is administered to manage severe hypertension and reduce elevated blood pressure.

Major companies operating in the angina pectoris drugs market are Astellas Pharma Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Bausch Health Companies Inc., Merck & Co Inc., Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, Sun Pharmaceutical Industries Limited, Sanofi SA, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., Amgen Inc., GlaxoSmithKline plc, Lupin Pharmaceuticals Inc., Merck KGaA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., Servier Laboratories, Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Ipsen S.A., H. Lundbeck A/S.

North America was the largest region in the angina pectoris drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the angina pectoris drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the angina pectoris drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the angina pectoris drugs market by increasing the cost of imported raw materials and finished drug formulations, affecting production and pricing globally. Segments such as nitrates, beta-adrenergic blocking agents, and calcium channel blockers are particularly impacted, especially in regions like Asia-Pacific and Europe, which rely heavily on imports. While tariffs may increase costs, they also encourage local manufacturing initiatives and innovation, potentially strengthening domestic production capacities over time.

The angina pectoris drugs market research report is one of a series of new reports that provides angina pectoris drugs market statistics, including angina pectoris drugs industry global market size, regional shares, competitors with a angina pectoris drugs market share, detailed angina pectoris drugs market segments, market trends and opportunities, and any further data you may need to thrive in the angina pectoris drugs industry. This angina pectoris drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Angina pectoris drugs are medications prescribed to manage angina pectoris, a medical condition characterized by chest pain or discomfort that occurs when part of the heart does not receive sufficient blood and oxygen. These drugs help relieve chest pain or discomfort associated with coronary heart disease.

The major drug classes used for angina pectoris include nitrates, antiplatelet agents, beta-adrenergic blocking agents, calcium channel blockers, anti-ischemic agents, statins, antihypertensive agents, and other drugs. Nitrates and nitrites are compounds that contain nitrogen and oxygen atoms. Nitrates are commonly used in the treatment of angina pectoris, a condition involving chest pain or discomfort resulting from reduced blood flow to the heart. Their indications include stable angina, unstable angina, and Prinzmetal’s angina. Angina pectoris drugs are administered through oral, parenteral, transdermal, and other routes of administration and are used by hospitals, homecare settings, specialty clinics, and other end users.

The angina pectoris drugs market consists of sales of aspirin, ranolazine, and angiotensin-converting enzyme inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.